Individuals' experiences in genetic counseling and predictive testing for familial amyotrophic lateral sclerosis

被引:2
|
作者
Steigerwald, Connolly G. [1 ,2 ]
Bertolini, Carina [1 ]
McElhiney, Martin [3 ,4 ]
Bergner, Amanda L. [1 ,5 ]
Harms, Matthew B. [6 ]
Harrington, Elizabeth A. [1 ,6 ]
机构
[1] Columbia Univ, Vagelos Coll Phys & Surg, Genet Counseling Grad Program, New York, NY USA
[2] NYU Grossman Sch Med, Dept Neurol, Div Neurogenet, New York, NY 10016 USA
[3] Columbia Univ, Vagelos Coll Phys & Surg, Dept Psychiat, New York, NY USA
[4] New York State Psychiat Inst & Hosp, New York, NY USA
[5] Columbia Univ, Vagelos Coll Phys & Surg, Dept Genet & Dev, New York, NY USA
[6] Columbia Univ, Vagelos Coll Phys & Surg, Dept Neurol, New York, NY USA
关键词
decision making; genetic counseling; lived experience; predictive genetic testing; psychosocial; HUNTINGTONS-DISEASE; PSYCHOLOGICAL IMPACT; MUTATIONS; PENETRANCE; PROGNOSIS; DECISION; UPDATE; ALS;
D O I
10.1002/jgc4.1890
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
As clinical genetic testing in the amyotrophic lateral sclerosis (ALS) diagnostic setting increases, the identification of at-risk family members has also expanded. No practice guidelines specifically for predictive genetic testing exist, and few studies about the psychological impacts of testing in this subgroup have occurred, limiting the ability to tailor recommendations and counseling in this community. We surveyed asymptomatic individuals at risk for inheriting an ALS-associated gene mutation. The 80-question survey was designed using a combination of validated measures (General Anxiety Disorder; FACToR; Decision Regret Scale) and original items. Ninety participants completed the survey, including those who completed predictive genetic testing (N = 42) and those who did not (N = 48). Gene positive individuals experienced greater negativity, uncertainty, and overall psychological impairment (p = 0.002; p < 0.001; p = 0.001). Individuals who had not undergone testing reported thinking about their risk multiple times per day and experiencing more decisional regret than those who tested (p = 0.006). In terms of decision-making, being prepared for potential clinical drug trials was a more important potential benefit among those who underwent testing (p = 0.026). Participants valuing preparedness for clinical drug trials supports the concept that genetic testing for ALS will increase as research in gene-targeted therapeutics progresses. This study describes factors relevant to the genetic testing decision-making process and adaptation to results from the perspective of at-risk individuals, which can ultimately guide genetic counseling practice in this population.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Genetic counseling and diagnostic genetic testing for familial amyotrophic lateral sclerosis and/or frontotemporal dementia: A qualitative study of client experiences
    Crook, Ashley
    Jacobs, Chris
    Newton-John, Toby
    McEwen, Alison
    JOURNAL OF GENETIC COUNSELING, 2022, 31 (05) : 1206 - 1218
  • [2] Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians
    Roggenbuck, Jennifer
    Quick, Adam
    Kolb, Stephen J.
    GENETICS IN MEDICINE, 2017, 19 (03) : 267 - 274
  • [3] Impact of presymptomatic genetic testing for familial amyotrophic lateral sclerosis
    Fanos, Joanna H.
    Gronka, Susan
    Wuu, Joanne
    Stanislaw, Christine
    Andersen, Peter M.
    Benatar, Michael
    GENETICS IN MEDICINE, 2011, 13 (04) : 342 - 348
  • [4] Patients with sporadic and familial amyotrophic lateral sclerosis found value in genetic testing
    Wagner, Karin N.
    Nagaraja, Haikady N.
    Allain, Dawn C.
    Quick, Adam
    Kolb, Stephen J.
    Roggenbuck, Jennifer
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2018, 6 (02): : 224 - 229
  • [5] Toward genetic counseling practice standards for diagnostic testing in amyotrophic lateral sclerosis and frontotemporal dementia
    Crook, Ashley
    Jacobs, Chris
    Newton-John, Toby
    McEwen, Alison
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2022, 23 (7-8) : 562 - 574
  • [6] Predictive genetic testing for amyotrophic lateral sclerosis and frontotemporal dementia: genetic counselling considerations
    Crook, Ashley
    Williams, Kelly
    Adams, Lorel
    Blair, Ian
    Rowe, Dominic B.
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2017, 18 (7-8) : 475 - 485
  • [7] Genetic testing for amyotrophic lateral sclerosis in Canada - an assessment of current practices
    Salmon, Kristiana
    Anoja, Nancy
    Breiner, Ari
    Chum, Marvin
    Dionne, Annie
    Dupre, Nicolas
    Fiander, Amanda
    Fok, Daniel
    Ghavanini, Amer
    Gosselin, Sylvie
    Izenberg, Aaron
    Johnston, Wendy
    Kalra, Sanjay
    Matte, Genevieve
    Melanson, Michel
    O'Connell, Colleen
    Ritsma, Benjamin
    Schellenberg, Kerri
    Shoesmith, Christen
    Tremblay, Sandra
    Williams, Heather
    Genge, Angela
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2022, 23 (3-4) : 305 - 312
  • [8] Clinical and genetic basis of familial amyotrophic lateral sclerosis
    Sgobbi de Souza, Paulo Victor
    Vieira de Rezende Pinto, Wladimir Bocca
    Troccoli Chieia, Marco Antonio
    Bulle Oliveira, Acary Souza
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2015, 73 (12) : 1026 - 1037
  • [9] Genetic Testing for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia: Impact on Clinical Management
    Roggenbuck, Jennifer
    Fong, Jamie C.
    CLINICS IN LABORATORY MEDICINE, 2020, 40 (03) : 271 - +
  • [10] Familial Amyotrophic Lateral Sclerosis
    Boylan, Kevin
    NEUROLOGIC CLINICS, 2015, 33 (04) : 807 - +